Several thousands of myopic patients have undergone photo refractive keratectomy (PRK) worldwide (prior to the publication of long-term, carefully controlled stud ies). The evidence in support of the currently widespread use of topical corticosteroids after PRK, however, is lim ited. We report the results of a prospective, double masked trial to determine the effect of dexamethasone 0.1 % on refraction and anterior stromal haze following -3.00 and -6.00 dioptre PRK procedures (n = 113; mini mum follow-up 1 year). Initially the reduction in myopia was significantly greater in the steroid group compared with the placebo group (p<0.002). However, on discon tinuing the corticosteroids at 3 months this difference became statistically insignificant (p>0.2). There was no statistically significant effect on anterior stromal haze at any stage. We conclude that, in view of their side effects, it would be unacceptable to use topical corticosteroids in the long term to maintain the initial beneficial effect on refraction. We therefore consider that topical cortico steroids should not be used following PRK.
Following laboratory, animal and blind eye studies in sev eral centres, photorefractive keratectomy (PRK) with the argon fluoride excimer laser has been used increasingly around the world over the past 3 years for the treatment of simple myopia. The interaction of excimer laser radiation with the corneal surface (photoablation) results in highly precise removal of tissue. By interposing a computer controlled iris diaphragm in the beam a graded exposure can be achieved and the central cornea flattened to effect a reduction of myopia. However, the precision with which the corneal surface can be repro filed has been shown to be overshadowed by the individual variation in wound heal ing, which results in a variable degree of loss of corneal transparency (haze) and regression of the induced refrac tive change.1.2 Since the individual variation increases with depth of ablation,2 predictability has been described as only 'fair' for low degrees of myopia,2 Anterior stromal haze and loss of refractive correction have both been shown to be correlated with depth of ablation3 and there fore in order to improve predictability and limit side effects the wound healing response following excimer laser PRK must be modulated. Currently there is consider able interest in pharmacological manipulation of this response.
In an earlier paper we discussed the evidence in support of topical corticosteroids in the treatment of corneal injuries including incisions.3 The superficial wide area excisions which result from excimer laser photoablation, however, are very different from the wounds encountered clinically or those used in laboratory models when inves tigating the role of these agents. In addition, there is only limited evidence from one study using a rabbit model that topical corticosteroids might have a beneficial effect on corneal haze, and no animal data to suggest that there might be an effect on refractive outcome. 4 In spite of this limited evidence in support of topical corticosteroids all groups investigating PRK in sighted eyes have used a ster oid regimen. 1,2,5-9 There has also been a suggestion that the frequency of administration of these drops can be titrated against the post-operative progress of both anterior stro mal haze and rate of regression. 5, 6 In addition, there is con siderable variatlOn in treatment parameters and post-operative regimens from centre to centre as high lighted in our previous paper. 3 We demonstrated that corneal clarity can be improved in a number of superficial pathologies and none of these patients received steroids.lO In addition, in our blind eye PRK series -7.00 dioptre (D) ablations were performed (on axis ablation depth of 44 Jlm) and no corticosteroids were used. 1 Average haze was noted to be less than that seen in our original sighted eye cohort (n = 120, fol low-up 2 years)I,2 although mean age was greater in the blind eye series. Ethics committee constraints based on current clinical experience of corneal wound healing and the above animal study led to all patients in the original sighted eye cohort receiving high-dose topical cortico steroids. In spite of this, considerable haze, regression and individual variation were reported. 1 ,2 In addition, 21 patients from the original cohort defaulted on the cortico steroid regimen and there was no discernible difference in either haze or regression between this group and the main body of the cohort.
In view of the limited evidence in support of cortico steroids post-PRK, the individual variation and the like lihood of side effects with these agents, we designed a prospective, randomised, age-matched, double-masked trial to address the question: Do topical corticosteroids influence haze or refraction post-PRK? We reported the results of the 6-month follow-up of this trial in which it was found that topical corticosteroids had a significant beneficial effect on refraction while administered but that this effect became statistically insignificant when steroids were discontinued.3 This paper reports the I-year fol low-up of the same cohort.
MATERIAL S AND METHOD S

Patient Selection
Following ethics committee approval, prospective patients were sent background information and a ques tionnaire. The selection criteria have been described pre viously and are summarised in Table 1.3 To minimise variation between patients resulting from a variety of attempted corrections we planned to perform only -3.00D and -6.00D corrections (ablation depths 25 and 44 Jlm respectively). This also allowed investigation of the effects of topical dexamethasone 0.1 % at two discrete ablation depths. We therefore selected patients with pre operative refraction close to -3.00D (-2.88D ± 0.37D) and -6.00D (-5.96D ± 0.53D). Emmetropia was not, therefore, the aim in every case. Sample size for statistical significance was calculated using the variance of the data from our original cohort of 120 patientsY 1. Refraction. The accuracy of refraction was assumed to be of the order of ±0.50D. In the -3.00D group we con sidered that a l.OOD difference between placebo and ster oid groups would be regarded as clinically significant, and a 2.00D difference in the -6.00D group.
2.
Haze. Given the difficulty in assessing haze subjec tively, I -3 we considered that a 1 + difference between groups would be clinically significant.
The minimum total sample sizes required (calculated to give the standard 80% chance of detecting a difference at the 5% significance level) were therefore n = 36 for the -3.00D group and n = 50 for the -6.00D group.
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Age and Sex
In the -3.00D group (n = 57) the mean age was 35.51 years, SD 8.1 (range 24-58 years). The male to female (M:F) ratio was 23:34.
In the -6.00D group (n = 56) the mean age was 39.6 years, SD 9.87 (range 24-66 years). The M:F ratio was 21:35.
Pre-operative Assessment
The details of the pre-operative assessment have been reported previously. Briefly, this comprised general oph thalmic examination, subjective refraction, variable con trast visual acuity assessment and ultrasonic axial length measurement. The 113 patients recruited into the study were coded and placed in 'steroid' or 'placebo' groups by random, age-matched allocation. The final numbers in each group were:
Group A (-3.00D steroid group): n = 29, mean pre-oper ative refraction = -2.94D (SD = 0.38D, range -2.125D to -3.625D).
Group B (-3.00D placebo group): n = 28, mean pre operative refraction = -2.82D (SD = 0.36D, range -2.25D to -3.50D).
Group C (-6.00D steroid group): n = 28, mean pre-oper ative refraction = -5.90D (SD = 0.54D, range -5.00D to -7.00D).
Group D (-6.00D placebo group): n = 28, mean pre operative refraction = -6.02D (SD = 0.51D, range -4.75D to -7.00D).
The Choice o/Topical Corticosteroid
The placebo and steroid preparations were identical in every respect except for the presence or absence of dex amethasone 0.1 %. This steroid was chosen for its proven therapeutic efficacy and ability to penetrate the cornea readily. 11-1 3 To achieve an appearance, taste and pH identi cal to the placebo a buffered solution of the metasul- Table I 
Motivation
Prospective patients asked to state their reasons for wishing to be included in the trial. Only those with realistic expectations included phobenzoate salt was used. Thiomersal 0.005% was present in both placebo and steroid preparations.
Corticosteroid Regimen
The corticosteroid regimen was x5 per day for 2 months, x4 per day for 2 weeks, x3 per day for 1 week, twice per day for 1 week, once per day for 1 week then discontinued. All patients were counselled at great length regarding the aims of the trial and the importance of compliance.
The Procedure
A Summit Technology UV200 excimer laser was used with an emission wavelength of 193 nm, a fixed pulse rep etition rate of 10 Hz and aradiant exposure of 180 mJ/cm2 at the cornea. There was no effluent removal and no eye stabilising system. The laser, which had been serviced immediately prior to the trial, was calibrated at the begin ning of each day and printouts were obtained at the begin ning, middle and end of each session (to confirm energy output). As many treatment parameters as possible were kept constant, including the ablation rate (0.22 11m per pulse) and the maximum beam diameter (4 mm). A detailed consent form was signed prior to the procedure. Patients were allocated randomly to one of the two sur geons (D.S.G., M.G.K.M.), both of whom used a stan dardised surgical technique as described previously.I -3 Patients were required to fixate a target light within the laser aperture for the duration of the procedure; this was 10 seconds and 17 seconds for -3.00D and -6.00D correc tions respectively. To ensure uniformity of treatment para meters and ease of follow-up allII3 patients were treated in a 2-week period (July 1991).
Post-operative Management/Monitoring
The treatment regimen immediately post-procedure was identical in each case and comprised oral analgesics, mydriasis and Oc chloramphenicol 1 % and pad. Adminis tration of the study drops commenced the following day when the pad was removed, and neither the surgeon nor the patient knew which trial drops were being instilled. The study was therefore 'double-masked'. The post-oper ative follow-up schedule has been described in detail elsewhere.3
RESULTS
From our previous studies 1,2 we noted that stabilisation of refraction occurred after 3--4 months and that anterior stromal haze was maximal at 5-6 months. We therefore decided to break the code to determine patient assignation after the 6-month visit.
Allergic Response
Nine patients (8%) suffered an allergic response to thio mersal and were therefore excluded from the main cohort. This reaction occurred by the second week in each case and took the form of hyperaemia, watering and lid oedema. On breaking the code all but one of these patients was found to have been using the placebo preparation.
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Intraocular Pressure (lOP) Increase
A significant rise in lOP (>5 mmHg) occurred in 12 patients (11 %). In 2 of these lOP was in excess of 40 mmHg; therefore the eyedrops were discontinued and these 2 patients were excluded from the trial. The maxi mum lOP in the remaining 10 patients, prior to the final month of treatment, was 22 mmHg and, as the eyedrops were about to be administered in reducing doses, the regimen was completed as per the protocol. All patients with raised lOP belonged to the steroid groups. The final number in each group was therefore: -3.00D: n = 50 (27 in the steroid group, 23 in the placebo group) -6.00D: n = 52 (27 in the steroid group, 25 in the placebo group)
Refractive Outcome
The mean change in refraction with time for the -3.00D and -6.00D groups up to and including the I-year visit is shown in Fig. 1 and Table II . An initial overcorrection fol lowed by regression to a plateau with significant under correction at around 3 months is common to both groups. As reported previously, in the first 3 months the mean change in refraction for the placebo groups ( Fig. Ia and b , broken line) is consistently less than that of the groups using steroid. However, by the third month in the -3.00D group there is no statistically significant difference between steroid and placebo(p = 0.1; 95% confidence interval -O. IO, 1.01). All data were found to be normally distributed and therefore two-tailed Student's t-tests were used.) By the sixth month there was no significant differ ence in either the -3.00D or -6.00D groups (p = 0.62 and 0.2 respectively; 95% confidence intervals -0.43, 0.71 and -0.43, 2.00 respectively). Similarly, at 1 year no sig nificant difference could be demonstrated between the two groups in spite of a 0.28D difference between the means in the -3.00D group and a 0.78D difference in the -6.00D group (p = 0.45 and 0.2 respectively; 95% confidence intervals -0.40, 0.70 and -0.38, 1.96 respectively). There was no statistically significant difference in mean change in refraction between the third, sixth and twelfth months in either group. In order to demonstrate the individual varia tion encountered all data points at I-year follow-up are represented on a scattergram (Fig. 2) .
Anterior Stromal Haze
The time course for the development of anterior stromal haze, as assessed subjectively on slit lamp examination, is shown in Fig. 3 . In the -3.00D groups, with and without steroids, haze appears to be maximal at around 3 months, while in the -6.00D group haze is maximal at 5-6 months. As reported previously, there was no statistically signifi cant difference in haze between the steroid and placebo groups at any stage (all p values >0.05). The same is true of the I-year data. A downward trend is seen for both groups in which anterior stromal haze reduces between the sixth and twelfth months. The mean subjective haze grad- ing at 12 months in the -3.00D group is 0.5 while for the -6.000 group the value is 0.74. Having used two discrete ablation depths it is possible also to demonstrate that the amount of haze is highly statistically significantly greater in the -6.000 group.
Axial Length
As reported previously, there was no correlation between axial length and either change in refraction or subjective haze grading.
Complications
Complications are listed in Table III . The number of patients demonstrating a loss of best spectacle corrected visual acuity in each of the four subgroups (-3.000 pla cebo and steroid, -6.00D placebo and steroid) is small and no significant difference between these groups could be demonstrated in terms of this loss. The change in best spectacle corrected Snellen visual acuity (100% contrast) is shown in Fig. 4 for both the 6 -month and l2-month visits. At 6 months 20% of individuals had lost one or more lines of Snellen acuity and one individual had lost three lines (anterior stromal haze is maximal at around this stage). Eighteen per cent lost half a line while the visual acuity of 41 % remained unchanged. Twenty-three per cent gained between a half and one line, presumably due to increased retinal image size (Fig. 4a) . At the I-year stage best corrected spectacle acuity had improved in some of those individuals who had experienced a reduction at the 6-month stage. Fifteen per cent lost between one and two lines and no patient lost more than two lines. Interestingly, only 6% showed an improvement of half a line and 5% of one line (Fig. 4b) .
DISCUSSION
At this relatively early stage in the clinical application of excimer laser photoablation it can not be assumed that top ical corticosteroids can be used successfully to modify wound healing following PRK. Experimental evidence for this assumption is limited.4 Previous phototherapeutic keratectomy (PTK) and blind eye studies have indicated that where topical corticosteroids are not administered the degree of haze encountered is not significantly greater than that seen in sighted eye PRK trials in which steroids are used in all patients. 1 ,2,7-1 0 Where individuals have defaulted there has been no apparent detrimental effect on either refractive outcome or anterior stromal haze. 1 ,2 ... ...
Attempted Correction (0) Because of the widespread use of the procedure and the considerable individual variation seen in the wound heal ing response following PRK I -3 it is important to ascertain whether corticosteroids have a significant effect on refrac tion, anterior stromal haze and other complications.
Refractive Outcome
As reported previously, the mean change in refraction was statistically significantly greater in the corticosteroid group (i.e. corticosteroids have a beneficial effect on refraction) in the first 3 months after PRK (Fig. 1 , Table  II ). In the -3.00D group no statistically significant differ ence in refraction was found beyond (and including) the 3 -month stage. In the -6.00D group a statistically signifi cant difference exists up to 3 months but this significance
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is lost by 6 months. At the I -year stage dexamethasone had been discontinued for 9 months and no statistically significant difference between placebo and corticosteroid groups was demonstrated. This would indicate that if corticosteroids have an effect it is sustained only during their administration. The difference between the mean change in refraction comparing steroid with placebo groups at 1 year is O.28D (-3.00D group) and O.78D (-6.00D group). While these differences, particularly in the -6.00D group, would seem to be beneficial they are not statistically significant. If topical corticosteroids can be used to reduce cellular activity (either epithelial hyperplasia or collagen syn thesis) then it would be expected that their effects will be maximal in the first few post -operative months when there is marked stromal remodelling and maximal keratocyte· activity. Once this initial healing phase is over it might be expected that beneficial effects from steroid adminis tration would be sustained, since in all histopathological studies stromal changes beyond this period are small.I4-1 7 In contrast, any corticosteroid effect after the first 3 months would not be due to large -scale collagen remodell ing but might be related to direct effects on epithelial cells or hydration of the stroma. Anecdotal reports from centres using flexible corticosteroid regimens in the first 6 post operative months suggest that regression can be reversed and anterior stromal haze reduced by increasing the dose or reinstating treatment with topical steroids (Seiler and Ten groth, personal communication).
These findings are not at odds with the results of the present study since we have demonstrated a statistically significant beneficial effect on refraction while topical steroids are used in the first few months after PRK. Because of possible side effects 1 8-20 the present study was not designed to investigate the effect of long -term regular use of topical corticosteroids. It is therefore not possible to comment on the likely outcome had these agents been continued in high doses beyond the 3 -month stage. If the statistically beneficial effect seen in the first 3 months could be sustained by continued administration then the problem remains as to how long these potentially harmful agents can be used with impunity. This is of particular rel evance in the context of refractive surgery where the eye is, in all other respects, healthy.
It should be noted that the same overall trend to under correction with considerable individual variation, as seen in our original cohort,I,2 was evident in all four groups (Figs. 1, 2) . In both the -3.00D and -6.00D groups (with and without steroids) it can be seen that some patients have regressed to their pre-operative refraction while over correction is uncommon (Fig. 2) .
Anterior Stromal Haze
Anterior stromal haze, assessed at the slip lamp, was found to increase to a maximum at around 3 months in the -3.00D groups and at between 5 and 6 months in the -6.00D groups (Fig. 3) . No statistically significant difference in haze was demonstrated between the steroid and placebo groups at any stage of follow-up. The same results were obtained when objective assessment of haze (described previously3.2 1 ,22) was used, although the abso- lute time course for development of haze differs slightly. Again no statistically significant difference was found between the corticosteroid and control groups. Both sub jective and objective haze grading show considerable indi vidual variation, suggesting that differences in wound healing are responsible for the spectrum of haze seen. As previously reported,3 the amount of anterior stromal haze correlated only poorly with reduction in best spec tacle corrected Snellen acuity. The number of patients who experienced a loss of Snellen acuity within each of the four groups was relatively small and precludes the appli cation of meaningful confidence limits. It is of interest, however, that anterior stromal haze shows a downward trend from 6 months to 1 year (Fig. 3) for all groups and that in the same period there is an overall improvement in those patients who experienced a loss of best spectacle corrected visual acuity (Fig. 4) . At 6 months one patient, who was in the -6.00D steroid group, had lost three lines of Snellen acuity while at the I-year stage the deficit had improved, in keeping with the general trend, to one and a half lines.
We have been able to confirm that there is a highly sig nificant statistical correlation between anterior stromal haze and the depth of the induced ablation (p<0.001) and a moderately good correlation between haze and regres sion (R = 0.75 on average).3
Axial Length
We reported in our previous series that high myopes underwent greater regression and developed greater haze than medium myopes undergoing the same correction.
1,2
However, there was no relationship between axial length and anterior stromal haze or refractive outcome.
The present study shows that topical corticosteroids have a significant beneficial effect on refraction while used in the first 3 months following excimer laser photorefractive ker atectomy. However, beyond 3 months, at which time ster oids were discontinued, no statistically significant difference in refraction could be demonstrated. Anterior stromal haze was not influenced by the presence or absence of steroids at any stage. It can be hypothesised that the use of high-dose topical corticosteroids beyond 3 months may sustain the beneficial effect on refraction and minimise regression, but this would be at the expense of side effects from these agents. We conclude, therefore, that topical corticosteroids should not be used following photorefractive keratectomy. Studies are under way to investigate the effects of other agents which may be of use in modulating the wound healing response after this new form of refractive surgery.
